Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MAGNETIC: Fenofibrate for Cardiovascular Protection in Type 2 Diabetes
NCT05542147Completed
- Start
- Jul 2022
- Primary completion
- Nov 2024
- Countries
- 1
01
Overview
Randomised, triple-blind trial in cardiovascular disease (CVD) comparing Fenofibrate with Placebo (2 arms). Primary endpoint: Endothelial Function at 12 weeks. Started Jul 2022; status: completed.
02
Drugs
fenofibrate
03
Conditions
cardiovascular disease (CVD)
Beyond the preview
Go deeper on NCT05542147.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05542147.